Back to top
more

Illumina (ILMN)

(Delayed Data from NSDQ)

$149.76 USD

149.76
1,714,060

+5.62 (3.90%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $149.78 +0.02 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Anika Reports Top Line Data from CINGAL Study, Shares Slump

Anika Therapeutics' (ANIK) shares declined 37%, after the company reported disappointing data from its phase III Cingal 16-02 study in treating patients with osteoarthritis (OA) in the knee.

    Tirthankar Chakraborty headshot

    4 of the Best Efficient Stocks to Buy for Superb Returns

    We have considered four popular ratios in order to find efficient companies that have the potential to provide impressive returns

      Novo Nordisk in Deal with Kallyope for Obesity, Diabetes Drugs

      Novo Nordisk (NVO) enters into a research collaboration and option agreement with Kallyope, Inc. to develop novel therapies for diabetes and obesity.

        Alexion (ALXN) Submits Application for ALXN1210 with FDA

        Alexion Pharmaceuticals, Inc. (ALXN) submits a Biologics License Application (BLA) to the FDA for approval of ALXN1210 to treat patients with paroxysmal nocturnal hemoglobinuria (PNH).

          Walgreens Boots' Retail Pharmacy Strong Despite Several Woes

          Walgreens Boots' (WBA) consistent sales rise in the Retail Pharmacy International business is encouraging. Moreover, the company steadily gains traction from a slew of strategic deals.

            BSX or BAX: Which is a Better Pick for Your Portfolio Now?

            After considering various parameters and fundamentals, we help you make a choice between Boston Scientific (BSX) and Baxter (BAX).

              Valeant Down as FDA Refuses to Approve Duobrii For Psoriasis

              Valeant (VRX) suffers a setback as the FDA issues a CRL for its plaque psoriasis lotion, Duobrii.

                QIAGEN (QGEN) Banks on Molecular Diagnostics, Global Growth

                QIAGEN's (QGEN) progress with the test menu expansion is impressive. Earlier in Q1, the company also secures the Japanese approval for QuantiFERON-TB Gold Plus as an in vitro diagnostic to detect TB.

                  Hologic's New Panther Fusion System Gets Health Canada Nod

                  Hologic's (HOLX) receipt of Health Canada approval for the new Panther Fusion system and Panther Fusion assays, for respiratory virus infections, is expected to boost the top line in the near term.

                    Here's Why You Should Add Amedisys (AMED) to Your Portfolio

                    Amedisys' (AMED) solid performance in the recently launched Personal Care segment buoys optimism. A favorable demographic trend and strategic acquisitions also bode well for the company.

                      Medtronic's Expanded IN.PACT Admiral FDA Nod to Aid APV Arm

                      Medtronic's (MDT) receipt of FDA approval for 200mm and 250mm lengths of the IN.PACT Admiral Drug-Coated Balloon (DCB) is expected to boost the top line.

                        Ryan McQueeney headshot

                        Anatomy of Success: Illumina (ILMN)

                        If investors had followed our ranking system when it flagged innovative biotech company, they would have witnessed massive profits.

                          Dr. Reddy's/Mylan Get FDA Nod for First Generic of Suboxone

                          Dr. Reddy's (RDY) and Mylan announced that the FDA approved the first generic version of Suboxone (Buprenorphine and Naloxone Sublingual Film) under-the-tongue film for the treatment of opioid addiction.

                            Flex Pharma Down on Workforce Reduction, Ends Phase II Study

                            Flex Pharma (FLKS) announced that the company is ending the phase II studies for its pipeline candidate FLX-787 in two indications. The company also plans to lower its workforce by about 60%.

                              Roche's (RHHBY) Avastin Gets Label Expansion Approval by FDA

                              Roche (RHHBY) announced that the FDA has approved the label expansion for its oncology drug Avastin in combination with chemotherapy, for the treatment of women with advanced ovarian cancer following initial surgical resection.

                                Iovance Biotherapeutics (IOVA) Jumps: Stock Rises 5.1%

                                Iovance Biotherapeutics (IOVA) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

                                  CVS Health's PBM Selling Season Remains Solid, Retail Grows

                                  CVS Health (CVS) significantly advances more than halfway through its 2019 renewals. Also, strong year-over-year Retail/LTC comparisons are encouraging.

                                    Pacific Biosciences to Gain From New Genome Sequencing Tools

                                    Pacific Biosciences' (PACB) new multiplexing kit to make genome sequencing faster and cost-effective.

                                      Here's Why You Should Invest in Genomic Health (GHDX) Now

                                      Genomic Health (GHDX) gains ground on promising reimbursement prospects for its Oncotype DX breast cancer test and solid international scenario.

                                        ResMed Reports Positive Results for Bilevel PAP Device Study

                                        Positive results from the Bilevel Rescue study are expected to boost the uptake of ResMed's (RMD) bilevel devices.

                                          STERIS (STE) Benefits From Core Business Expansion, Buyouts

                                          STERIS' (STE) strong organic growth across specialty services, life sciences and applied sterilization segments raises optimism on the stock.

                                            Amedisys (AMED) Buys Back 2.4M Shares From KKR, Stock Up

                                            Amedisys (AMED) works on its strategy to deploy capital in an accretive manner, maintaining low leverage and substantial borrowing capacity for future investment.

                                              Medtronic's (MDT) CRHF Arm Growth Strong, Rising Costs a Woe

                                              The gradually stabilizing Cardiac Rhythm & Heart Failure (CRHF) market increases investor confidence in the Medtronic (MDT) stock.

                                                Bristol-Myers (BMY) Reports Data from CheckMate-214 Study

                                                Bristol-Myers Squibb (BMY) announces encouraging data from the phase III CheckMate -214 study.

                                                  Boston Scientific Grows on New Products Amid Recall Issues

                                                  Boston Scientific's (BSX) 2018 guidance raises optimism for the company's near-term prospects.